| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Benhur Lee | |
| Kasopefoluwa Y Oguntuyo | |||
| Christian S Stevens | |||
| P2860 | cites work | Computational prediction of furin cleavage sites by a hybrid method and understanding mechanism underlying diseases | Q24632000 |
| Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. | Q30354466 | ||
| Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection | Q30447031 | ||
| Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites | Q37138587 | ||
| Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. | Q53633695 | ||
| A Novel Coronavirus from Patients with Pneumonia in China, 2019 | Q86729469 | ||
| SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor | Q88292103 | ||
| Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation | Q89108866 | ||
| The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade | Q89712904 | ||
| Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses | Q89866691 | ||
| Tetraspanins: Architects of Viral Entry and Exit Platforms | Q90646337 | ||
| Coronavirus membrane fusion mechanism offers as a potential target for antiviral development | Q91766933 | ||
| Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 | Q91807337 | ||
| Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction | Q92008873 | ||
| Another Decade, Another Coronavirus | Q92920684 | ||
| A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells | Q94500293 | ||
| Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications? | Q96228296 | ||
| Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies | Q96429196 | ||
| Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus | Q96870819 | ||
| Inhibiting Fusion with Cellular Membrane System: Therapeutic Options to Prevent Severe Acute Respiratory Syndrome Coronavirus-2 Infection | Q97596702 | ||
| ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain | Q97638457 | ||
| Distinct conformational states of SARS-CoV-2 spike protein | Q97642571 | ||
| Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial | Q97680790 | ||
| TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells | Q97680833 | ||
| A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction | Q97681534 | ||
| A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition | Q98185469 | ||
| Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection | Q98283058 | ||
| A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors | Q99569212 | ||
| Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models | Q101166587 | ||
| Spike mutation D614G alters SARS-CoV-2 fitness | Q101237615 | ||
| A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia | Q102373883 | ||
| SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity | Q103001453 | ||
| SARS-CoV-2, Early Entry Events | Q104143177 | ||
| D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization | Q104286443 | ||
| D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction | Q104799886 | ||
| Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis | Q105098704 | ||
| The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types | Q105550767 | ||
| Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion | Q107108504 | ||
| Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation | Q107324544 | ||
| Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin | Q107392243 | ||
| The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets | Q107473210 | ||
| SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells | Q107473262 | ||
| The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2 | Q107473264 | ||
| The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways | Q107473785 | ||
| N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 | Q107675443 | ||
| Structural impact on SARS-CoV-2 spike protein by D614G substitution | Q108393067 | ||
| Coronavirus entry: how we arrived at SARS-CoV-2 | Q108396471 | ||
| Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection | Q108396534 | ||
| The SARS-CoV-2 Spike variant D614G favors an open conformational state | Q110137155 | ||
| SARS-CoV-2 infection of the oral cavity and saliva | Q110457413 | ||
| Neutrophil Elastase and Proteinase 3 Cleavage Sites Are Adjacent to the Polybasic Sequence within the Proteolytic Sensitive Activation Loop of the SARS-CoV-2 Spike Protein | Q111271451 | ||
| Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants | Q111271452 | ||
| SARS-CoV-2 mutation 614G creates an elastase cleavage site enhancing its spread in high AAT-deficient regions | Q111271453 | ||
| Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V | Q111271454 | ||
| Avoiding culture shock with the SARS-CoV-2 spike protein | Q111271455 | ||
| Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera | Q111271457 | ||
| Analyzing the vast coronavirus literature with CoronaCentral | Q111271458 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | SARS-CoV-2 | Q82069695 |
| spike glycoprotein [SARS-CoV-2] | Q87917585 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 49-58 | |
| P577 | publication date | 2021-10-01 | |
| P1433 | published in | Current opinion in virology | Q26842394 |
| P1476 | title | Proteases and variants: context matters for SARS-CoV-2 entry assays | |
| P478 | volume | 50 |
| Q111271413 | Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein | cites work | P2860 |
Search more.